Determinants of pneumococcal vaccination among patients with chronic obstructive pulmonary disease in Spain

Human Vaccines

Volumn 2, Issue 3, 2006, Pages 99-104

  Ariñez Fernandez, Maria C ^a   Carrasco Garrido, Pilar ^a   Garcia Carballo, Marta ^a   Hernández Barrera, Valentín ^a   De Miguel, Ángel Gil ^a   Jiménez García, Rodrigo ^a,b  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

^b Facultad de Ciencias de la Salud   (Spain)

Author keywords

COPD; Streptococcus pneumoniae; Vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HEALTH STATUS; HUMAN; INFLUENZA VACCINATION; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PHYSICIAN; PRIMARY MEDICAL CARE; SPAIN; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 33748072466     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.2756     Document Type: Article

References (67)

1. Anto JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001; 17:982-94.
2. Rennard S, Decramer M, Calverley PMA, Pride NB, Soriano JB, Vermeire PA, Vestbo J. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002; 20:799-805.
3. Tzanakis N, Anagnostopoulou U, Filaditaki V, Christaki P, Siafakas N. Prevalence of COPD in Greece. Chest 2004; 125:892-900.
4. Pena VS, Miravitlles M, Gabriel R, Jimenez-Ruiz CA, Villasante C, Masa JF, Fernandez-Fau L. Geographic Variations in Prevalence and Underdiagnosis of COPD: Results of the IBERPOC Multicentre Epidemiological Study. Chest 2000; 118:981-9.
5. Miravitlles M, Mayordomo C, Artes M, Sanchez-Agudo L, Nicolau F, Segu JL. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitacion Obstructiva al Flujo aEreo. Respir Med 1999; 93:173-9.
6. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:1608-13.
7. Barbera JA, Peces-Barba G, Agusti AG, Izquierdo JL, Monso E, Montemayor T , Viejo JL, Sociedad Española de Neumologia y Cirugia Toracica. (SEPAR). (Clinical guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease]. Arch Bronconeumol 2001; 37:297-316.
8. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347:465-71.
9. Riquelme R, Torres A, El Ebiary M, de la Bellacasa JP, Estruch R, Mensa J Fernandez-Sola J, Hernandez C, Rodriguez-Roisin R.. Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med 1996; 154:1450-5.
10. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46:1-24.
11. Ruiz M, Ewig S, Marcos MA, Martinez JA, Arancibia F, Mensa J, Torres A.. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999; 160:397-405.
12. Ruiz-Gonzalez A, Falguera M, Nogues A, Rubio-Caballero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med 1999; 106:385-90.
13. Zalacain R, Torres A, Celis R, Blanquer J, Aspa J, Esteban L, Menendez R, Blanquer R, Borderias L; Pneumonia in the elderly working group, Area deTuberculosis e Infecciones Respiratorias. Community-acquired pneumonia in the elderly: Spanish multicentre study. Eur Respir J 2003; 21:294-302.
14. Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, McGeer A, Farley MM, Vugia DJ, Lexau C, Stefonek KR, Patterson JE, Jorgensen JH.. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90:223-9.
15. Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, Damaske B, Stefonek K, Barnes B, Patterson J, Zell ER, Schuchat A, Whitney CG; Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA 2001; 285:1729-35.
16. Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS, Breiman RF. Cigarette Smoking and Invasive Pneumococcal Disease. N Engl J Med 2000; 342:681-9.
17. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Streptococcus pneumoniae, 2003 preliminary. Available at 〈http://www.cdc.gov/ncidod/dbmd/ abcs/survreports/spneumo03prelim.pdf〉. Accessed November 18, 2005.
18. Instituto de Salud Pública-Consejería de Sanidad.Comunidad de Madrid. Campańa de Vacunación Antigripal y Antineumocó cica 2003. Technical document.
19. Bogaert D, van der Valk P, V, Ramdin R, Sluijter M, Monninkhof E, Hendrix R de Groot R, Hermans PW. Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infect Immun 2004; 72:818-23.
20. WHO position paper. Pneumococcal vaccines. Weekly epidemiological record 14. 2003; 110-19.
21. Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Laara E, Leinonen M, Kivela SL, Makela PH. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999; 17:2493-500.
22. Ortqvist A, Hedlund J, Burman LA, Elbel E, Hofer M, Leinonen M Lindblad I, Sundelof B, Kalin M. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998; 351:399-403.
23. Koivula MD I, Sten MD M, Leinonen MD M, Makela MD PPH. Clinical Efficacy of Pneumococcal Vaccine in the Elderly: A Randomized, Single-Blind Population-Based Trial. The American Journal of Medicine 1997; 103:281-90.
24. Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract 2000; 1:1.
25. Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 2001; 19:4780-90.
26. Watson L, Wilson BJ, Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 2002; 20:2166-73.
27. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453-60.
28. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993; 270:1826-31.
29. Farr BM, Johnston BL, Cobb DK, Fisch MJ, Germanson TP, Adal KA , Anglim AM. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med 1995; 155:2336-40.
30. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol 2004; 19:353-63.
31. Puig-Barbera J, Belenguer VA, Goterris PM, Brines Benlliure MJ. (Pneumococcal vaccine effectiveness in the elderly. Systematic review and meta-analysis]. Aten Primaria 2002; 30:269-81.
32. LeBaron CW, Chaney M, Baughman AL, Dini EF, Maes E, Dietz V, Bernier R. Impact of measurement and feedback on vaccination coverage in public clinics, 1988-1994. JAMA 1997; 277:631-5.
33. Guerin N. Assessing immunization coverage: how and why? Vaccine 1998; 16 Suppl:S81-3.
34. Kamal KM, Madhavan SS, Amonkar MM. Determinants of adult influenza and pneumonia immunization rates. J Am Pharm Assoc 2003; 43:403-11.
35. Honkanen PO, Keistinen T, Kivela SL. The impact of vaccination strategy and methods of information on influenza and pneumococcal vaccination coverage in the elderly population. Vaccine 1997; 15:317-20.
36. CDC. Influenza and pneumococcal vaccination levels among persons aged ≥65 years-United States, 2001. MMWR Morb Mortal Wkly Rep 2002; 51:1019-24.
37. Centers for Disease Control and Prevention. Racial/ethnic disparities in influenza and pneumococcal vaccination levels among persons aged > or =65 years-United States, 1989-2001. MMWR Morb Mortal Wkly Rep 2003; 52:958-62.
38. CDC. Public health and aging: influenza vaccination coverage among adults aged > or =50 years and pneumococcal vaccination coverage among adults aged ≥65 years-United States, 2002. MMWR Morb Mortal Wkly Rep 2003; 52:987-92.
39. Gonzalez de Aledo A. Vacunación antineumocócica en adultos de Cantabria: estrategias de captación y cobertura. Vacunas 2004;5[2p]:38-42.
40. Singleton JA, Greby SM, Wooten KG, Walker FJ, Strikas R. Influenza, pneumococcal, and tetanus toxioid vaccination of adults-United States, 1993-7. MMWR CDC Surveill Summ 2000; 49:39-62.
41. Nichol KL. Ten-year durability and success of an organized program to increase influenza and pneumococcal vaccination rates among high-risk adults. Am J Med 1998; 105:385-92.
42. Opstelten W, Hak E, Verheij TJ, van Essen GA. Introducing a pneumococcal vaccine to an existing influenza immunization program: vaccination rates and predictors of noncompliance. Am J Med 2001; 111:474-9.
43. Zubizarreta R, Cancelas M J. La introducción de la vacunación sistemática frente a las enfermedades neumocócicas en Galicia en el año 2000. Vacunas 2001; 2:135-41.
44. Instituto de Salud Pública.Consejería de Sanidad.Comunidad de Madrid. Campãa de Vacunación Antigripal y Antineumocócica 2004. Documente técnico. 2004.
45. Garcia MM, Carrasco P, Jimenez R, Martin A, Gobartt E, Gil A. Estudio epidemiológico para valorar la calidad de vida y el consumo de recursos sanitarios en los pacientes con enfermedad pulmonar obstructiva crónica (EPIDEPOC). Metodología y resultados iniciales. Medicinageneral 67, 485-490. 2004. Available at: http://www.semg.es/revista/revista_67/pdf/485_490. pdf
46. Jimenez-Garcia R, Arinez-Fernandez MC, Garcia-Carballo M, Hernandez-Barrera V, de Miguel AG, Carrasco-Garrido P. Influenza vaccination coverage and related factors among Spanish patients with chronic obstructive pulmonary disease. Vaccine. 2005; 23:3679-86.
47. Ministerio de Sanidad y Consumo.España. Vacunación de adultos, 2004. Documento de la Ponencia de Programas y Registro de Vacunaciones. Publicatión del Ministerio de Sanidad y Consumo. 2004.
48. Jimenez R, Larrauri A, Carrasco P, Esteban J, Gomez-Lopez LI, Gil A. Influenza coverages in Spain and vaccination-related factors in the subgroup aged 50-64 years. Vaccine 2003; 21:3550-5.
49. Marco JL, Martin Berra JC, Corres IM, Luque DR, Zubillaga GG. [Chronic obstructive lung disease in the general population. An epidemiologic study performed in Guipuzcoa]. Arch Bronconeumol 1998; 34:23-7.
50. Bovier PA, Chamot E, Bouvier GM, Loutan L. Importance of patients' perceptions and general practitioners' recommendations in understanding missed opportunities for immunisations in Swiss adults. Vaccine 2001; 19:4760-7.
51. Nowalk MP, Zimmerman RK, Feghali J. Missed opportunities for adult immunization in diverse primary care office settings. Vaccine 2004; 22:3457-63.
52. Shenson D, DiMartino D, Bolen J, Campbell M, Lu PJ, Singleton JA. Validation of self-reported pneumococcal vaccination in behavioral risk factor surveillance surveys: experience from the sickness prevention achieved through regional collaboration (SPARC) program. Vaccine 2005; 23:1015-20.
53. Brotons B, Perez JA, Sanchez-Toril F, Soriano S, Hernandez J, Belenguer JL. [The prevalence of chronic obstructive pulmonary disease and asthma. A cross-sectional study]. Arch Bronconeumol 1994; 30:149-52.
54. Krzyzanowski M, Kauffmann F. The relation of respiratory symptoms and ventilatory function to moderate occupational exposure in a general population. Results from the French PAARC study of 16,000 adults. Int J Epidemiol 1988; 17:397-406.
55. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR Surveill Summ 2002; 51:1-16.
56. Montnemery P, Adelroth E, Heuman K, Johannisson A, Johansson SA, Lindholm LH, Lundback B, Lofdahl CG. Prevalence of obstructive lung diseases and respiratory symptoms in southern Sweden. Respir Med 1998; 92:1337-45.
57. Petersen RL, Saag K, Wallace RB, Doebbeling BN. Influenza and pneumococcal vaccine receipt in older persons with chronic disease: a population-based study. Med Care 1999; 37:502-9.
58. National Center for Health Statistics. Early Release of Selected Estimates Based on Data from the January-March 2004 National Health Interview Survey. Available at: 〈http://www.cdc.gov/nchs/data/nhis/earlyrelease/ 200409_05.pdf〉 Accessed October 28, 2004.
59. Sarria A, Timoner J. [Determination of influenza vaccination in persons 65 years of age and older]. Rev Esp Salud Publica 2002; 76:17-26.
60. Zhang P, Tao G, Irwin KL. Utilization of preventive medical services in the United States: a comparison between rural and urban populations. J Rural Health 2000; 16:349-56.
61. Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med 1999; 130:397-403.
62. Christenson B, Lundbergh P, Hedlund J, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet 2001; 357:1008-11.
63. Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine 1999; 17 Suppl 1:S91-3.
64. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999; 159:2437-42.
65. MacDonald D, Baken L, Nelson A, Nichol KL. Validation of self-report of influenza and pneumococcal vaccination status in elderly outpatients. Am J Prev Med 1999; 16:173-7.
66. Zimmerman RK, Raymond M, Janosky JE, Nowalk MP, Fine MJ. Sensitivity and specificity of patient self-report of influenza and pneumococcal polysaccharide vaccinations among elderly outpatients in diverse patient care strata. Vaccine 2003; 21:1486-91.
67. Quinley JC, Shin A. Improving physician coverage of pneumococcal vaccine: a randomized trial of a telephone intervention. J Community Health 2004; 29:103-15.